Latest Data of InnoCare’s Orelabrutinib Presented at the 66th Annual Meeting of ASH

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

InnoCare 2024 Q3 Results Earnings Call

InnoCare to Hold 2024 R&D Day on November 14, 2024

InnoCare Announces Phase II Study Results of TYK2 Inhibitor ICP-488 Meet Primary Endpoint in Psoriasis Patients

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024

InnoCare Announces End-of-Phase 2 Meeting with FDA and Agreement to Initiate a Phase III clinical trial of orelabrutinib for the treatment of PPMS

InnoCare Business Update Conference Call

InnoCare Releases 2024 Interim Results and Business Highlights

InnoCare to Host 2024 Interim Results Earnings Call on August 21, 2024

British Journal of Cancer: Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumors with on-target resistance to first-generation agents